nefazodone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1890 83366-66-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • serzone
  • nefazodone
  • nefazodone hydrochloride
  • nefazodone HCl
an antidepressant for oral administration with a chemical structure unrelated to selective serotonin reuptake inhibitors, tricyclics, tetracyclics, or monoamine oxidase inhibitors (MAOI), inhibits neuronal uptake of serotonin and norepinephrine
  • Molecular weight: 470.01
  • Formula: C25H32ClN5O2
  • CLOGP: 5.53
  • LIPINSKI: 1
  • HAC: 7
  • HDO: 0
  • TPSA: 51.62
  • ALOGS: -3.83
  • ROTB: 10
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.40 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 18.24 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 20 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.51 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 7.50 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.01 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.20 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 22, 1994 FDA BRISTOL MYERS SQUIBB

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 44.08 33.35 29 505 310658 63177830

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Intentional overdose 45.28 35.01 19 493 105941 79637935
Drug hypersensitivity 44.26 35.01 26 486 298890 79444986

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N06AX06 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTIDEPRESSANTS
Other antidepressants
MeSH PA D000928 Antidepressive Agents
MeSH PA D018687 Antidepressive Agents, Second-Generation
MeSH PA D002491 Central Nervous System Agents
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D014179 Neurotransmitter Uptake Inhibitors
MeSH PA D011619 Psychotropic Drugs
MeSH PA D058830 Serotonin 5-HT2 Receptor Antagonists
MeSH PA D018490 Serotonin Agents
MeSH PA D000068760 Serotonin and Noradrenaline Reuptake Inhibitors
MeSH PA D012702 Serotonin Antagonists
CHEBI has role CHEBI:35469 antidepressants
CHEBI has role CHEBI:37890 alpha-adrenergic receptor blockaders
CHEBI has role CHEBI:48279 serotonin antagonists
CHEBI has role CHEBI:50949 SSRI
FDA EPC N0000175696 Serotonin Reuptake Inhibitor

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Major depressive disorder indication 370143000
Bipolar affective disorder, current episode depression off-label use 191627008 DOID:3312
Suicidal thoughts contraindication 6471006
Myocardial infarction contraindication 22298006 DOID:5844
Hypovolemia contraindication 28560003
Dehydration contraindication 34095006
Upper gastrointestinal hemorrhage contraindication 37372002
Low blood pressure contraindication 45007003
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Cerebrovascular disease contraindication 62914000 DOID:6713
Substance abuse contraindication 66214007
Epilepsy contraindication 84757009 DOID:1826
Liver function tests abnormal contraindication 166603001
Angina pectoris contraindication 194828000
Cerebrovascular accident contraindication 230690007
Mania contraindication 231494001
Disease of liver contraindication 235856003 DOID:409




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 6.98 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Sodium-dependent noradrenaline transporter Transporter INHIBITOR Kd 6.44 WOMBAT-PK CHEMBL
Sodium-dependent serotonin transporter Transporter INHIBITOR Kd 6.70 WOMBAT-PK CHEMBL
5-hydroxytryptamine receptor 2A GPCR ANTAGONIST Ki 8 WOMBAT-PK CHEMBL
5-hydroxytryptamine receptor 1A GPCR Ki 7.10 WOMBAT-PK
5-hydroxytryptamine receptor 2C GPCR Ki 7.14 PDSP
Alpha-1A adrenergic receptor GPCR Ki 7.79 WOMBAT-PK
Alpha-2B adrenergic receptor GPCR Ki 6.64 WOMBAT-PK
Histamine H1 receptor GPCR Ki 6.43 WOMBAT-PK
Sodium-dependent dopamine transporter Transporter Kd 6.44 WOMBAT-PK
Acetylcholinesterase Enzyme IC50 5.98 CHEMBL
Bile salt export pump Transporter IC50 5.38 CHEMBL
D(2) dopamine receptor GPCR Ki 6.75 WOMBAT-PK
Cytochrome P450 3A4 Enzyme INHIBITOR Ki 6 IUPHAR
5-hydroxytryptamine receptor 1A GPCR Ki 7.28 CHEMBL
Sodium-dependent serotonin transporter Transporter Ki 6.86 CHEMBL
Sodium-dependent dopamine transporter Transporter Ki 5.62 CHEMBL
5-hydroxytryptamine receptor 2A GPCR Ki 8.15 CHEMBL
Transporter Transporter Ki 6.24 CHEMBL
Bile salt export pump Transporter IC50 4.76 CHEMBL

External reference:

IDSource
4020893 VUID
N0000148387 NUI
D00819 KEGG_DRUG
82752-99-6 SECONDARY_CAS_RN
4020893 VANDF
C0068485 UMLSCUI
CHEBI:7494 CHEBI
CHEMBL623 ChEMBL_ID
CHEMBL1200492 ChEMBL_ID
DB01149 DRUGBANK_ID
C051752 MESH_SUPPLEMENTAL_RECORD_UI
7247 IUPHAR_LIGAND_ID
5432 INN_ID
59H4FCV1TF UNII
4449 PUBCHEM_CID
151679 RXNORM
1633 MMSL
47455 MMSL
5160 MMSL
d03808 MMSL
005051 NDDF
005052 NDDF
108435006 SNOMEDCT_US
108436007 SNOMEDCT_US
372491002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Nefazodone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0093-1024 TABLET 100 mg ORAL ANDA 32 sections
Nefazodone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0093-1024 TABLET 100 mg ORAL ANDA 32 sections
Nefazodone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0093-1025 TABLET 200 mg ORAL ANDA 32 sections
Nefazodone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0093-1025 TABLET 200 mg ORAL ANDA 32 sections
Nefazodone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0093-1026 TABLET 250 mg ORAL ANDA 32 sections
Nefazodone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0093-1026 TABLET 250 mg ORAL ANDA 32 sections
Nefazodone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0093-7113 TABLET 150 mg ORAL ANDA 32 sections
Nefazodone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0093-7113 TABLET 150 mg ORAL ANDA 32 sections
Nefazodone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0093-7178 TABLET 50 mg ORAL ANDA 32 sections
Nefazodone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0093-7178 TABLET 50 mg ORAL ANDA 32 sections
NEFAZODONE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 16590-166 TABLET 100 mg ORAL ANDA 33 sections
Nefazodone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 21695-174 TABLET 100 mg ORAL ANDA 30 sections
Nefazodone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 21695-175 TABLET 150 mg ORAL ANDA 30 sections
Nefazodone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 21695-176 TABLET 200 mg ORAL ANDA 30 sections
Nefazodone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 21695-177 TABLET 250 mg ORAL ANDA 30 sections
Nefazodone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 63629-7046 TABLET 150 mg ORAL ANDA 32 sections